[O-11] Oral Session 11

[O-11-6] First interim report of survey on long-term use of Inebilizumab for NMOSD

Kazuo Fujihara¹, Kyouko Okumura², Hideaki Hida², Saori Yamauchi², Satoshi Yuki², Shinya Hirota², Yoshito Nagano² (1.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan, 2.Mitsubishi Tanabe Pharma Corporation, Japan)